NM 501
Alternative Names: NM-501Latest Information Update: 26 Apr 2023
At a glance
- Originator Neuramedy
- Class Diagnostic agents
- Mechanism of Action Alpha-synuclein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research CNS disorders
Most Recent Events
- 13 Apr 2023 Early research in CNS disorders (Diagnosis) in South Korea (unspecified route) (Neuramedy pipeline April 2023)